Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2

Journal of Clinical Oncology

Volumn 28, Issue 14, 2010, Pages 2404-2410

  Malone, Kathleen E ^a   Begg, Colin B ^a   Haile, Robert W ^a   Borg, Ake ^a   Concannon, Patrick ^a   Tellhed, Lina ^a   Xue, Shanyan ^a   Teraoka, Sharon ^a   Bernstein, Leslie ^a   Capanu, Marinela ^a   Reiner, Anne S ^a   Riedel, Elyn R ^a   Thomas, Duncan C ^a   Mellemkjær, Lene ^a   Lynch, Charles F ^a   Boice Jr , John D ^a   Anton Culver, Hoda ^a   Bernstein, Jonine L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN, HUMAN;

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CONTRALATERAL BREAST CANCER; CONTROLLED STUDY; FEMALE; FRAMESHIFT MUTATION; GROUPS BY AGE; HETEROZYGOTE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MISSENSE MUTATION; MUTATIONAL ANALYSIS; NONSENSE MUTATION; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SECOND CANCER; SPLICING DEFECT; TUMOR SUPPRESSOR GENE; AGE; BREAST TUMOR; CANCER REGISTRY; CLINICAL TRIAL; DENMARK; GENETIC PREDISPOSITION; GENETICS; HEALTH SURVEY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; STATISTICAL MODEL; TIME; TREATMENT OUTCOME; TUMOR RECURRENCE; UNITED STATES;

ADULT; AGE FACTORS; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CASE-CONTROL STUDIES; DENMARK; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LOGISTIC MODELS; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; POPULATION SURVEILLANCE; RISK ASSESSMENT; RISK FACTORS; SEER PROGRAM; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 77952518033     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.24.2495     Document Type: Article

References (38)

1. Antoniou A, Pharoah PD, Narod S, et al: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet 72:1117-1130, 2003 (Pubitemid 36530000)
2. Begg CB, Haile RW, Borg A, et al: Variation of breast cancer risk among BRCA1/2 carriers. JAMA 299:194-201, 2008
3. Easton DF, Ford D, Bishop DT: Breast and ovarian cancer incidence in BRCA1-mutation carriers: Breast Cancer Linkage Consortium. Am J Hum Genet 56:265-271, 1995
4. Risch HA, McLaughlin JR, Cole DE, et al: Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: A kin-cohort study in Ontario, Canada. J Natl Cancer Inst 98:1694-1706, 2006 (Pubitemid 44942707)
5. Struewing JP, Hartge P, Wacholder S, et al: The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401-1408, 1997 (Pubitemid 27208598)
6. Bernstein JL, Thompson WD, Risch N, et al: Risk factors predicting the incidence of second primary breast cancer among women diagnosed with a first primary breast cancer. Am J Epidemiol 136:925-936, 1992
7. Chen Y, Thompson W, Semenciw R, et al: Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarkers Prev 8:855-861, 1999 (Pubitemid 29508719)
8. Curtis RE, Freedman DM, Ron E, et al: New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. Bethesda, MD, National Cancer Institute, NIH publication 05-5302, 2006
9. Foulkes WD, Wong N, Brunet JS, et al: Germline BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer. Clin Cancer Res 3:2465-2469, 1997 (Pubitemid 28133169)
10. Foulkes WD, Chappuis PO, Wong N, et al: Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome. Ann Oncol 11:307-313, 2000 (Pubitemid 30214668)
11. Robson M, Gilewski T, Haas B, et al: BRCA-associated breast cancer in young women. J Clin Oncol 16:1642-1649, 1998
12. Robson M, Levin D, Federici M, et al: Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. J Natl Cancer Inst 91:2112-2117, 1999 (Pubitemid 30019573)
13. Robson M, Svahn T, McCormick B, et al: Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: A clinic-based series. Cancer 103:44-51, 2005 (Pubitemid 39665455)
14. Verhoog LC, Brekelmans CT, Seynaeve C, et al: Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 351:316-321, 1998 (Pubitemid 28052696)
15. Verhoog LC, Brekelmans CT, Seynaeve C, et al: Survival in hereditary breast cancer associated with germline mutations of BRCA2. J Clin Oncol 17:3396-3402, 1999 (Pubitemid 29517906)
16. Verhoog LC, Berns EM, Brekelmans CT, et al: Prognostic significance of germline BRCA2 mutations in hereditary breast cancer patients. J Clin Oncol 18:119S-124S, 2000 (suppl)
17. Stoppa-Lyonnet D, Ansquer Y, Dreyfus H, et al: Familial invasive breast cancers: Worse outcome related to BRCA1 mutations. J Clin Oncol 18:4053-4059, 2000 (Pubitemid 32038397)
18. Eccles D, Simmonds P, Goddard J, et al: Familial breast cancer: An investigation into the outcome of treatment for early stage disease. Fam Cancer 1:65-72, 2001 (Pubitemid 35221517)
19. Metcalfe K, Lynch HT, Ghadirian P, et al: Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 22:2328-2335, 2004 (Pubitemid 41115389)
20. Kirova YM, Stoppa-Lyonnet D, Savignoni A, et al: Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. Eur J Cancer 41:2304-2311, 2005 (Pubitemid 41415607)
21. Pierce LJ, Levin AM, Rebbeck TR, et al: Tenyear multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 24:2437-2443, 2006 (Pubitemid 46630619)
22. Brekelmans CT, Tilanus-Linthorst MM, Seynaeve C, et al: Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer 43:867-876, 2007 (Pubitemid 46366688)
23. El-Tamer M, Russo D, Troxel A, et al: Survival and recurrence after breast cancer in BRCA1/2 mutation carriers. Ann Surg Oncol 11:157-164, 2004 (Pubitemid 40486790)
24. Robson ME, Chappuis PO, Satagopan J, et al: A combined analysis of outcome following breast cancer: Differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 6:R8-R17, 2004
25. Bernstein JL, Langholz B, Haile RW, et al: Study design: Evaluating gene-environment interactions in the etiology of breast cancer - The WECARE study. Breast Cancer Res 6:R199-R214, 2004
26. Langholz B, Borgan O: Counter-matching: A stratified nested case-control sampling method. Biometrika 82:69-79, 1995
27. Surveillance Research Program, National Cancer Institute, SEER*Stat Software, Version 6.3.6. Bethesda, MD, 2007. http://www.seer.cancer.gov/ seerstat/
28. Surveillance, Epidemiology, and End Results (SEER) Program: SEER*Stat Database: Incidence, SEER 9 Regs Limited Use, Nov 2006 Sub (1973-2004), linked to County Attributes, Total U.S. 1969-2004 Counties. http://seer.cancer.gov/data/citation.html
29. Ries LAG, Melbert D, Krapcho M, et al: SEER Cancer Statistics Review, 1975-2005. http://seer.cancer.gov/csr/1975-2005/
30. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases: Anglian Breast Cancer Study Group. Br J Cancer 83:1301-1308, 2000
31. Anton-Culver H, Cohen PF, Gildea ME, et al: Characteristics of BRCA1 mutations in a population-based case series of breast and ovarian cancer. Eur J Cancer 36:1200-1208, 2000 (Pubitemid 30407006)
32. Malone KE, Daling JR, Doody DR, et al: Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. Cancer Res 66:8297-8308, 2006 (Pubitemid 44299201)
33. Peto J, Collins N, Barfoot R, et al: Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 91:943-949, 1999 (Pubitemid 29272520)
34. Whittemore AS, Gong G, John EM, et al: Prevalence of BRCA1 mutation carriers among U.S. non-Hispanic Whites. Cancer Epidemiol Biomarkers Prev 13:2078-2083, 2004 (Pubitemid 40054301)
35. Brekelmans CT, Seynaeve C, Menke-Pluymers M, et al: Survival and prognostic factors in BRCA1-associated breast cancer. Ann Oncol 17:391-400, 2006 (Pubitemid 43329574)
36. Graeser MK, Engel C, Rhiem K, et al: Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 27:5887-5892, 2009
37. Goffin JR, Chappuis PO, Bégin LR, et al: Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data. Cancer 97:527-536, 2003 (Pubitemid 36125829)
38. Eng C, Brody LC, Wagner TM, et al: Interpreting epidemiological research: Blinded comparison of methods used to estimate the prevalence of inherited mutations in BRCA1. J Med Genet 38:824-833, 2001 (Pubitemid 34014207)